Evidence map›Paper›PMID 35804307›Full record

Trial reportBMC cancer2022

Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial.

Edward Yu, Alison L Allan, Michael Sanatani, Debra Lewis, Andrew Warner, A Rashid Dar, Brian P Yaremko, Lori E Lowes, David A Palma, Jacques Raphael and 9 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00907543 (Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00907543 nacompletednot on this map

Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy (Cisplatin, 5-FU and Radiotherapy Followed by Surgery) to Surgery Followed by Postoperative Chemoradiation (Cisplatin, Epirubicin, 5-FU, Radiotherapy) for Esophageal Cancer

TypeinterventionalSponsorRichard MalthanerRan2009 to 2018Enrolled96ConditionsEsophageal NeoplasmsArmsPreoperative treatment of chemotherapy and radiation, Postoperative treatment of chemotherapy and radiation
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Liquid biopsies in cancer.Molecular biomedicine · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Co-design of a cancer nutrition care pathway by patients, carers, and health professionals: the CanEAT pathway.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Edward YuDepartment of Oncology, Divisions of Radiation Oncology, Western University, 1151 Richmond Street, London, Ontario, N6A3K7, Canada. eyu@uwo.ca.
Alison L AllanExperimental Oncology, London, Ontario, Canada.
Michael SanataniMedical Oncology, London, Ontario, Canada.
Debra LewisThoracic Surgery and Surgical Oncology, London, Ontario, Canada.
Andrew WarnerDepartment of Oncology, Divisions of Radiation Oncology, Western University, 1151 Richmond Street, London, Ontario, N6A3K7, Canada.
A Rashid DarDepartment of Oncology, Divisions of Radiation Oncology, Western University, 1151 Richmond Street, London, Ontario, N6A3K7, Canada.
Brian P YaremkoDepartment of Oncology, Divisions of Radiation Oncology, Western University, 1151 Richmond Street, London, Ontario, N6A3K7, Canada.
Lori E LowesPathology & laboratory medicine, London Health Science Centre, London, Ontario, Canada.
David A PalmaDepartment of Oncology, Divisions of Radiation Oncology, Western University, 1151 Richmond Street, London, Ontario, N6A3K7, Canada.
Jacques RaphaelMedical Oncology, London, Ontario, Canada.
Mark D VincentMedical Oncology, London, Ontario, Canada.
George B RodriguesDepartment of Oncology, Divisions of Radiation Oncology, Western University, 1151 Richmond Street, London, Ontario, N6A3K7, Canada.
Dalilah FortinThoracic Surgery and Surgical Oncology, London, Ontario, Canada.
Richard I InculetThoracic Surgery and Surgical Oncology, London, Ontario, Canada.
Eric FrechetteDepartment of Thoracic Surgery and Surgical Oncology, Sherbrooke University, Sherbrooke, Quebec, Canada.
Joel BiererDepartment of Medicine, Western University, London, Ontario, Canada.
Jeffery LawDepartment of Medicine, Western University, London, Ontario, Canada.
Jawaid YounusMedical Oncology, London, Ontario, Canada.
Richard A MalthanerThoracic Surgery and Surgical Oncology, London, Ontario, Canada.
Western University · CASurgical Specialties (Canada) · CALondon Health Sciences Centre · CAUniversité de Sherbrooke · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy.

methodsWe prospectively collected CTC data from patients with operable non-metastatic esophageal cancer from April 2009 to November 2016 enrolled in our QUINTETT esophageal cancer randomized trial (NCT00907543). Patients were randomized to receive either neoadjuvant cisplatin and 5-fluorouracil (5-FU) plus radiotherapy followed by surgical resection (Neoadjuvant) or adjuvant cisplatin, 5-FU, and epirubicin chemotherapy with concurrent extended volume radiotherapy following surgical resection (Adjuvant). CTCs were identified with the CellSearch® system before the initiation of any treatment (surgery or chemoradiotherapy) as well as at 6-, 12-, and 24-months post-treatment. The threshold for CTC positivity was one and the findings were correlated with patient prognosis.

resultsCTC data were available for 74 of 96 patients and identified in 27 patients (36.5%) at a median follow-up of 13.1months (interquartile range:6.8-24.1 months). Detection of CTCs at any follow-up visit was significantly predictive of worse disease-free survival (DFS;hazard ratio [HR]: 2.44; 95% confidence interval [CI]: 1.41-4.24; p=0.002), regional control (HR: 6.18; 95% CI: 1.18-32.35; p=0.031), distant control (HR: 2.93; 95% CI: 1.52-5.65;p=0.001) and overall survival (OS;HR: 2.02; 95% CI: 1.16-3.51; p=0.013). After adjusting for receiving neoadjuvant vs. adjuvant chemoradiotherapy, the presence of CTCs at any follow-up visit remained significantly predictive of worse OS ([HR]:2.02;95% [Cl]:1.16-3.51; p=0.013) and DFS (HR: 2.49;95% Cl: 1.43-4.33; p=0.001). Similarly, any observed increase in CTCs was significantly predictive of worse OS (HR: 3.14; 95% CI: 1.56-6.34; p=0.001) and DFS (HR: 3.34; 95% CI: 1.67-6.69; p<0.001).

conclusionThe presence of CTCs in patients during follow-up after tri-modality therapy was associated with significantly poorer DFS and OS regardless of timing of chemoradiotherapy.

Indexed as

Esophageal NeoplasmsNeoplastic Cells, CirculatingCisplatinFluorouracilFollow-Up StudiesHumansPrognosisCisplatinFluorouracilCirculating tumor cellsEsophageal cancerNon-metastaticPrognostic

Identifiers

PMID35804307
PMCPMC9264673
OpenAlexW4284891587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.